Investor Presentaiton

Reported EBIT margin of 28%¹ in H1, reflecting an impact from cost inflation, increased level of commercial activity and amortisation costs H1 2022/23 EBIT margin development before special items (%) 31.3 -1.3 -1.6 -0.4 0.5 -0.1 28.3 -0.5 27.8 Reported EBIT margin H1 21/221 A Gross Δ Δ Admin- A R&D- margin Distribution- to-sales to-sales to-sales Δ Other operating items Reported EBIT margin H1 22/231 Currency EBIT margin effect H1 22/23 (Constant Currencies)1 1 Before special items of DKK 33 million in H1 22/23 related to integration costs for the Atos Medical acquisition, and DKK 415 million in H1 21/22, of which DKK 300 million related to Mesh litigation provisions and the remaining DKK 115 million related to the Atos Medical acquisition (one-off transaction costs, legal and advisory fees) 7 H1 2022/23 highlights Gross margin was 67%, against 69% in H1 last year Negative impact from: input cost inflation (raw materials, energy, freight), double-digit wage inflation in Hungary and ramp-up costs in Costa Rica Positive impact from: Atos Medical, price increases, country and product mix, operating leverage, and efficiency savings • Positive FX impact on gross margin of around 70 bps Operating expenses in H1 amounted to DKK 4,728 million. Operating expenses grew 9% from last year excl. inorganic operating expenses from Atos Medical (19% incl. inorganic OPEX). Atos Medical contributed with DKK 570 million, including DKK 107 million in amortisation costs. Distribution-to-sales ratio was 31%, compared to 29% last year Distribution costs were up 20% vs. last year, impacted by Atos Medical, increased sales & marketing activities and travel post COVID- 19, higher logistics costs, and continued commercial investments (Interventional Urology, consumer and digital, Atos Medical) The admin-to-sales ratio was 5%, compared to 4% last year. The R&D-to- sales ratio was 3%, compared to 4% last year EBIT before special items was DKK 3,445 million, a 3% increase from last year. Reported EBIT margin before special items was 28% compared to 31% last year (positive impact of 50 bps from FX) Coloplast

View entire presentation